Cue Biopharma (NASDAQ:CUE) Raised to Buy at Wall Street Zen
by Scott Moore · The Cerbat GemCue Biopharma (NASDAQ:CUE – Get Free Report) was upgraded by research analysts at Wall Street Zen to a “buy” rating in a report issued on Saturday.
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cue Biopharma in a research report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Cue Biopharma presently has a consensus rating of “Sell”.
Get Our Latest Research Report on Cue Biopharma
Cue Biopharma Price Performance
Shares of NASDAQ:CUE opened at $0.50 on Friday. The stock has a market cap of $48.82 million, a price-to-earnings ratio of -1.57 and a beta of 1.57. Cue Biopharma has a 12-month low of $0.17 and a 12-month high of $1.03. The business’s 50 day moving average is $0.28 and its 200 day moving average is $0.46.
Cue Biopharma (NASDAQ:CUE – Get Free Report) last announced its earnings results on Monday, March 16th. The company reported $0.01 earnings per share (EPS) for the quarter. Cue Biopharma had a negative return on equity of 165.19% and a negative net margin of 96.85%.The company had revenue of $21.94 million for the quarter. As a group, equities research analysts expect that Cue Biopharma will post -0.76 earnings per share for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Stifel Financial Corp boosted its position in Cue Biopharma by 25.4% in the fourth quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock worth $75,000 after purchasing an additional 50,000 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in shares of Cue Biopharma by 730.0% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock valued at $57,000 after buying an additional 73,000 shares during the last quarter. Squarepoint Ops LLC purchased a new position in shares of Cue Biopharma during the 3rd quarter valued at $62,000. Boothbay Fund Management LLC lifted its position in shares of Cue Biopharma by 15.3% during the 4th quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company’s stock valued at $215,000 after buying an additional 93,333 shares during the last quarter. Finally, Texas Capital Bank Wealth Management Services Inc lifted its position in shares of Cue Biopharma by 1,231.2% during the 4th quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company’s stock valued at $135,000 after buying an additional 407,568 shares during the last quarter. Hedge funds and other institutional investors own 35.04% of the company’s stock.
Cue Biopharma Company Profile
Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.
Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.